Comparison of loss of response between anti-tumor necrosis factor alone and combined use with immunomodulators in patients with inflammatory bowel disease
Seung Wook Hong, Jaewoo Park, Hyuk Yoon, Hye Ran Yang, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Joo Sung Kim
Korean J Intern Med. 2021;36(Suppl 1):S9-S17. Published online 2020 Jun 25 DOI: https://doi.org/10.3904/kjim.2019.279
Citations to this article as recorded by 
Effectiveness of strategies to suppress antibodies to infliximab in pediatric inflammatory bowel disease
Jasmijn Z. Jagt, Koen W. Holleman, Marc A. Benninga, Johan E. Van Limbergen, Nanne K. H. de Boer, Tim G. J. de Meij
Journal of Pediatric Gastroenterology and Nutrition.2024; 78(1): 57. CrossRef
MIF Variant rs755622 Is Associated with Severe Crohn’s Disease and Better Response to Anti-TNF Adalimumab Therapy
Gregor Jezernik, Mario Gorenjak, Uroš Potočnik
Genes.2023; 14(2): 452. CrossRef
Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review
Liang-Fang Wang, Ping-Run Chen, Si-Ke He, Shi-Hao Duan, Yan Zhang
World Journal of Gastroenterology.2023; 29(29): 4481. CrossRef
Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
Jihye Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2022; 37(5): 895. CrossRef
Vaccination strategies for Korean patients with inflammatory bowel disease
Yoo Jin Lee, Eun Soo Kim
The Korean Journal of Internal Medicine.2022; 37(5): 920. CrossRef
Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim
The Korean Journal of Internal Medicine.2022; 37(5): 906. CrossRef